2015 Antineoplastics

2014SESSION III OBJECTIVES: Drugs that disrupt DNA

  1. Outline the mechanism of action and the cell targets for crosslinking agents.  Understand why these agents are CCNS and why they are particularly beneficial in the treatment of the majority of human cancers.

  2. Identify the steps in the activation process of cyclophosphamide, and describe how this relates to its specific toxicity and the use of MESNA.  What are the implications of this activation process on drug interactions between cyclophosphamide and inducers/inhibitors of CYP2B6?

  3. Identify the toxicities that are common to all crosslinking agents. List the unique properties for each crosslinking agent.

  4. Compare the cytotoxic and secondary mechanisms of action of the anthracycline antibiotics.  Relate these actions to the specific toxicities associated with these drugs.  Define the characteristics (both acute and long-term) of the cardiomyopathy associated with dauno- and doxo-rubicin.

  5. Identify the resistance mechanisms for each of these agents, and be able to identify situations where multidrug resistance is likely to develop.

  6. Categorize the agents that cause strand breaks in terms of their specific mechanisms of action, and their chemical classes. Identify the unique properties of bleomycin that make it a useful component of many drug regimens.

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 5-may-15 6:14 PM